Harvard Business Review

JUNE 16, 2016

Although US firms had pioneered and dominated the technology for two decades, they were now getting pummeled by cheaper Japanese imports. The initial breakthrough came in 1987, but the first drug wasn’t approved until 2011. a leader in virtually every area of advanced technology. The Era of Big Science.

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

MAY 2, 2011

Without operating in the former, they won't be able to attain economies of scale; sans the latter, they're unlikely to continue developing state-of-the-art technologies. Moreover, it forgot that it will continue to do well in China and India not just by keeping costs low but also by developing new technologies.

Globalization 14

Globalization Marketing Venture Capitalist Biotechnology 14

Harvard Business Review

SEPTEMBER 14, 2011

In 2008, Dr Reddy's acquired Chirotech, Dow Chemical's R&D unit, for $32 million, and in April 2011 relocated it to a new 33,000 sq. Suzlon's head of technology is John O'Halloran, a former Cummins Engine executive who now leads Suzlon's 500-strong global R&D team out of Hamburg. facility in Cambridge Science Park.

Globalization 9

Globalization Innovation Decentralization Chemicals 9

Harvard Business Review

FEBRUARY 19, 2015

Kate had had a taste of entrepreneurial life — she was on the management team of ArtusLabs, the North Carolina-based software company that was bought by PerkinElmer in 2011 — and knew how “exciting it was to work at a start-up.” “I knew I wanted to be free to make these big decisions.” I have no regrets.”

Project 8

Project Outsourcing Learning-by-Doing Commitment 8

Harvard Business Review

MARCH 5, 2012

And one look at the trade deficit ($558 billion in 2011) clearly indicates we don't have as much as our foreign competitors to sell in return. Sure, with improvements in information technology and communication, some services are becoming more tradable and that creates opportunities for the U.S. The Right Policies.

Health Care 9

Health Care Biotechnology Industry Policies 9

Harvard Business Review

SEPTEMBER 11, 2014

That means new technologies and new competitors are hitting the market at an unprecedented rate. and technological uncertainty (can we make a desirable solution?) Technological uncertainty results from unknowns regarding the technologies that might emerge or be combined to create a new solution.

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22